

OMB No.: 0925-0740

Expiration Date: 07/31/2022

Public reporting burden for this collection of information is estimated to average 5 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-0740). Do not return the completed form to this address.

## Registration

<b>First Name*</b>	<b>Last Name*</b>
<input type="text"/>	<input type="text"/>
<b>Email*</b>	
<input type="text"/>	
<b>Confirm email*</b>	
<input type="text"/>	
<b>Institution*</b>	<b>State</b>
<input type="text"/>	<input type="text" value="- None -"/>
<b>Institution Type*</b>	
<input type="text" value="- Select -"/>	
<b>Position*</b>	
<input type="text" value="- Select -"/>	
<b>Years since terminal degree*</b>	
<input type="radio"/> N/A <input type="radio"/> < 5 <input type="radio"/> 5-10 <input type="radio"/> > 10	
<b>Area of research interest in drug development</b>	
<input type="checkbox"/> Early Drug Discovery: target validation, assay development, HTS, and hit-to-lead	
<input type="checkbox"/> Lead Optimization: SAR-based medicinal chemistry campaign and DMPK	
<input type="checkbox"/> Preclinical Development: in vivo proof-of-concept studies, preclinical PK/PD, mechanism of action studies, and non-clinical toxicology	
<input type="checkbox"/> Scale-up Synthesis and cGMP Manufacture	
<input type="checkbox"/> Clinical Development: clinical protocol development, regulatory considerations, biomarker development, and clinical trials	

## Select all upcoming sessions you would like to attend

- July 23, 2021, 12 pm – 2:30 pm ET, Session I: Grand Overview
- July 30, 2021, 12 pm – 2:30 pm ET, Session II: Pre-clinical Proof of Concept: Establishing Activity, Bioavailability, and Associated Effect, in Cancer Relevant Models
- August 6, 2021, 12 pm – 2:30 pm ET, Session III: Non-clinical Toxicology
- August 20, 2021, 12 pm – 2:30 pm ET, Session IV: Chemistry Manufacturing and Controls (CMC) for Small Molecules
- September 10, 2021, 12 pm – 2:30 pm ET, Session V: Development of Biological Products
- September 24, 2021, 12 pm – 2:30 pm ET, Session VI: Regulatory Considerations
- October 29, 2021, 12 pm – 2:30 pm ET, Session VII: Clinical Translation
- November 19, 2021, 12 pm – 2:30 pm ET, Session VIII: Entrepreneurship: Partnering and Advancing
- December 3, 2021, 12 pm – 2:30 pm ET, Session IX: NCI Translational Resources and Programs
- December 10, 2021, 12 pm – 2:30 pm ET, Session X: Case Studies

Submit